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INTRODUCTION
Cisplatin is an important and effective antineoplastic agent that 
inhibits several types of malignant neoplasms. DNA is believed 
to be the target of the antineoplastic activity because cisplatin 
binds irreversibly to DNA, forming intra-strand crosslinks be-
tween adjacent guanine residues. Cisplatin has severe side ef-
fects that limit its clinical use; these include ototoxicity, nephro-
toxicity, and neurotoxicity. Though the mechanism mediating 
the nephrotoxicity and ototoxicity is unknown, it is believed to 
be different from that involved in the drug’s anti-tumor activity. 
The most commonly reported histopathological manifestation of 
ototoxicity is outer hair cell (OHC) degeneration. However, the 
ototoxic effects of cisplatin are not limited to the auditory hair 
cells, and the stria vascularis and spiral ganglion cells are also af-
fected (1). Cisplatin-induced ototoxicity is related to changes in 
the antioxidant activity in the hair cells, particularly the OHCs 
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(2). Mitochondrial dysfunction caused by reactive oxygen spe-
cies has been implicated in the pathogenesis of cisplatin-induced 
ototoxicity (3). Boulikas and Vougiouka (4) reviewed that cispla-
tin directly induced apoptosis in auditory sensory cells through 
mitochondrial apoptotic pathways. The Bcl-2 family, cytochrome 
c, and caspase 3 are important elements in the caspase-depen-
dent pathway, and apoptosis-inducing factor (AIF), poly (ADP-
ribose) polymerase (PARP), and c-Jun N-terminal kinase (JNK) 
play critical roles in the caspase-independent pathway. AIF, a 
mitochondrial intermembrane protein, triggers apoptosis when 
it is released into the cytosol. Various strategies have been devel-
oped in the laboratory setting to prevent ototoxicity, though 
they are not widely used clinically. 
  Minocycline is a tetracycline derivative used as an antimicro-
bial agent to treat conditions such as acne. Many studies have 
confirmed the anti-inflammatory and neuroprotective properties 
of minocycline (5). Minocycline inhibits caspase-1 and caspase-3, 
which are involved in the generation of interleukin-1 and the in-
duction of apoptosis, respectively (6). Wang et al. (7) reported 
that, in addition to protecting neural cells, minocycline protect-
ed non-neuronal kidney epithelial cells against various agents 
inducing apoptosis through the enhancement of Bcl-2 expres-
sion. Corbacella et al. (8) investigated the effect of minocycline 
on gentamicin (GM)-induced ototoxicity, and reported that mi-
nocycline inhibited p38 MAP kinase phosphorylation and cas-
pase 3 activation.
  As cisplatin is commonly used for anti-tumor chemptherapy, 
its ototoxic effect is still a problem for those who suffer from 
malignant tumors. The aim of the present study was to investi-
gate the protective effect of minocycline on cisplatin induced 
ototoxicity and to identify the possible mechanism of action in 
vivo and in vitro.
METHODS
In vitro experiments
Cell culture
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM), supple-
mented with 10% fetal bovine serum (FBS) at 33°C under 5% 
CO2 in an incubator. In all experiments, 70-80% confluent cul-
tures were used.
Cell viability assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assay was used to measure HEI-OC1 cell viability af-
ter each treatment. HEI-OC1 cells were seeded at 10
5 cells/mL 
in 96-well plates and were maintained in DMEM with 10% FBS 
at 33°C with 5% CO2 in air. They were exposed to various con-
centrations of minocycline (Sigma-Aldrich Corp., St. Louis, MO, 
USA) for 24 hours to determine the proper concentration for the 
protection experiment. We then selected the 10 µM (4.59 µg/mL) 
of minocycline for further experiments, which was most protec-
tive and less toxic concentration for HEI-OC1 cells (Fig. 1A). 
Cells were divided into four groups: control, minocycline (mino), 
cisplatin (cis), and minocycline plus cisplatin (mino-cis). Minocy-
cline was administered 24 hours before cisplatin treatment. Cis-
platin was diluted repeatedly using the same volume of media, 
and the cells were incubated in the various concentrations for 
24 hours. MTT solution (2 mg/mL in phosphate-buffered saline 
[PBS]) was added (50 μL/well) after incubation and plates were 
further incubated for 2 hours at 33°C in 5% CO2 in air. The MTT 
solution was then removed and 100 μL dimethylsulfoxide 
(DMSO; Kanto Chemical Co., Tokyo, Japan) was added. After 
stirring the plate using a microplate mixer (Amersham, Pharma-
cia Biotech, Buckinghamshire, UK), the absorbance at a wave-
length of 540 nm was measured using a microplate reader (BIO-
RAD 550, Bio-Rad, Hercules, CA, USA). The percentage of cell 
viability was calculated using the following equation: Cell viabil-
Fig. 1. (A) Cell survival curve of House Ear Institute-Organ of Corti 1 
(HEI-OC1) cells cultured with minocycline. Minocyline (mino) is cyto-
toxic at high, but not at low, concentrations. (B) Cell survival curve of 
HEI-OC1 cells cultured with cisplatin alone and with cisplatin (cis) 
after minocycline pretreatment. More cells survived in the 10 µM mi-
nocycline pretreatment condition compared with the cisplatin alone 
condition. 
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ity (%)=mean optical density in the test well/mean optical den-
sity in the control well×100.
Western blot analysis
Following incubation for 24 hours in 10 µM minocycline, 4 µg/
mL cisplatin, 8 µg/mL cisplatin, minocycline plus cisplatin (4 µg/
mL and 8 µg/mL each) the cells and control plate were analyzed 
using Western blot analysis. The cells were collected and lysed in 
radio immunoprecipitation assay (RIPA) buffer (Sigma-Aldrich 
Co., St. Louis, MO, USA) and the protein concentration was de-
termined using the Bradford assay (Bio-Rad). Protein (100 µg) 
was loaded onto 12-15% polyacrylamide gels, subjected to elec-
trophoresis, and electrotransferred to polyvinylidene fluoride 
(PVDF) membranes (Bio-Rad). After blocking with 5% nonfat 
dry milk (in PBS containing 0.1% Tween 20) for 1 hour, the pri-
mary antibodies to cleaved caspase-3 (R&D Systems, Minneap-
olis, MN, USA), Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), p-c-Jun (Santa Cruz Biotechnology), AIF (Santa Cruz 
Biotechnology), PARP (Calbiochem, Germany), and GAPDH 
(Abcam, Cambridge, UK) were applied to the PVDF membranes. 
The membranes were probed with horseradish peroxidase-con-
jugated secondary IgG antibody for 1 hour. The proteins were 
detected by enhanced chemiluminescence (ECL), according to 
the manufacturer’s instructions (Amersham Biosciences). Quan-
titative analysis of the band density was carried out using Kodak 
molecular image software (In-vivo FX, New Haven, CT, USA).
Mitochondrial fractionation
AIF is a key protein in the caspase-independent cell death path-
way. We measured cytosolic AIF because it is released into the 
cytosol from mitochondria to trigger cell death. The cells were 
washed with ice-cold PBS and then resuspended in an isotonic 
homogenization buffer (20 mM Tris-HCl, pH 7.5, 0.25 M sucrose, 
10 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenyl-
methylsulfonyl fluoride, 1.5 mM MgCl2, 10 µg/mL leupeptin, 
and 2 µg/mL aprotinin). The cells were incubated in ice for 5 min 
and microcentrifuged for 10 minutes at 4°C. The supernatant 
was used as the cytosolic fraction.
In vivo experiments
Animals
We used 15 guinea pigs (200-300 g), free of external and middle 
ear pathology. All animals had free access to commercial food 
and water and were maintained in a temperature-controlled en-
vironment with a 12/12-hour light/dark cycle. Before the exper-
iment, the animals were anesthetized using an intramuscular in-
jection of a xylazine/ketamine cocktail (ketamine 75 mg/kg, xy-
lazine 5 mg/kg). Deep anesthesia was maintained during the ex-
periment using a half dose of xylazine/ketamine cocktail as re-
quired.
  The animals were divided into three groups. Group 1 (6 ani-
mals) received an intraperitoneal injection (i.p.) of minocycline 
(45 mg/kg) and received cisplatin (15 mg/kg, i.p.) 12 hours later, 
group 2 (6 animals) received cisplatin (15 mg/kg, i.p) and normal 
saline in an equal volume to the minocycline, and group 3 (3 
animals) received minocycline (45 mg/kg, i.p) and normal saline 
in an equal volume to the cisplatin. All chemicals were obtained 
from Sigma (St. Louis, MO, USA).
Auditory tests
The auditory brainstem response (ABR) was performed using a 
computer-based signal averaging system (Tucker-Davis Technol-
ogy, Alachua, FL, USA) to determine the auditory threshold. 
ABR was performed prior to drug administration and every 24 
hours for 5 days after drug treatment. An active electrode lead 
was positioned subcutaneously at the vertex and referred to the 
second electrode in the left infra-auricular area. The ground 
electrode was located on the contralateral ear. ABRs were re-
corded in an electrically shielded, double-walled sound booth in 
response to clicks and tone bursts at 8, 16, and 32 kHz. Each re-
sponse was averaged over a total of 500 times. Intensities were 
expressed in dB sound pressure level (SPL) peak equivalent, 
based on calibration. Sounds were presented in 10 dB steps, and 
ABR responses were recorded for each intensities.ABR thresh-
old was defined as the lowest intensity capable of eliciting a rep-
licable, visually detectable wave V.
Scanning electron microscopy 
Immediately after the completion of the follow-up ABRs, ani-
mals were decapitated and the cochleae were harvested. Cochle-
ae were immediately immersed in 2.5% glutaraldehyde in 0.1 
M cacodylate buffer. Small holes were made in the apex and the 
round and oval windows. The cochleae were fixed using a peri-
lymphatic perfusion of 2.5% glutaraldehyde in 0.1 M cacodyl-
ate buffer and were refrigerated overnight in the same solution. 
The following day, after rinsing with cacodylate buffer, the co-
chleae were postfixed with a slow perfusion of 1% osmium te-
troxide in 0.1 M cacodylate buffer. The bony capsule of the co-
chlea was thinned using a dental drill. The remaining bone and 
lateral wall were dissected away using fine forceps and a 26 gauge 
needle to expose the organ of Corti. Dissected cochleae were 
dehydrated in serially increasing concentrations of ethanol from 
50-100%, and were critical point-dried. Cochleae were mount-
ed on SEM stubs and were sputter-coated with platinum. Fully 
processed specimens were examined and photographed using a 
Hitachi S-3000N scanning electron microscope (Hitachi, Tokyo, 
Japan).
Statistical analysis
Statistical evaluation of the results was performed using SPSS 
ver. 10.0 (SPSS Inc., Chicago, IL, USA) with the significance 
level set at P<0.05. For comparison of the toxicity with serial 
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used. Mann-Whitney test was used for comparison of hearing 
before and after cisplatin treatment.
RESULTS
In vitro experiments
Cell viability assay 
Minocycline was cytotoxic at high, but not at low concentrations 
(Fig. 1A). Cisplatin was toxic in a dose-dependent manner and 
pretreatment with minocycline significantly decreased cisplatin-
induced toxicity at the concentrations between 0.5 and 16 µg/
mL (log rank test, P<0.05). No protective effect of minocycline 
was observed at higher concentrations of the drug (Fig. 1B).
Western blot analysis
Effect of minocycline on the caspase-dependent pathway: Bcl-2, 
and caspase 3
To determine whether minocycline inhibited cisplatin-induced 
caspase activation, cells were exposed to 4 µg/mL and 8 µg/mL 
cisplatin in the presence or absence of 10 µM minocycline. 
Cleaved caspase-3 expression increased in HEI-OC1 cells ex-
posed to cisplatin of two different concentrations by 2.22 (4 µg/
mL) and 2.32 (8 µg/mL) times as the control. Pretreatment with 
minocycline attenuated expression of cleaved caspase-3 by half 
in response to 4 µg/mL, but not 8 µg/mL of cisplatin. The ex-
pression of Bcl-2 was elevated by 2.3 (4 µg/mL cisplatin) and 
1.98 (8 µg/mL cisplatin) times respectively when minocycline 
was added to the cisplatin-treated cells (Fig. 2).
Effect of minocycline on the caspase-independent pathway: JNK, 
PARP, and AIP
JNK and PARP play important roles in the caspase-independent 
cell death pathway. To evaluate the role of the pathway in cispla-
tin-induced apoptosis in HEI-OC1 cells, we measured the ex-
pression of p-c-JUN and PARP. The expression of p-c-JUN in-
creased by 3.21 (4 µg/mL) and 15.0 (8 µg/mL) times, in a dose-
dependent manner, in the cis group. The expression was mark-
edly attenuated by minocycline pretreatment to the level of 2.26 
(4 µg/mL) and 8.04 (8 µg/mL) times as the control. The expres-
sion of cleaved PARP also increased by 8.19 (4 µg/mL) and 
16.98 (8 µg/mL) times, in a dose-dependent manner, in the cis 
group. The expression markedly attenuated by minocycline pre-
treatment to the level of 4.77 (4 µg/mL) and 12.8 (8 µg/mL) 
times as the control. AIF is a key protein in caspase-independent 
apoptosis pathway. Cytosolic AIF increased by 2.03 (4 µg/mL) 
and 1.79 (8 µg/mL) times in a dose-dependent manner in the cis 
group and decreased to 1.67 (4 µg/mL) and 1.11 (8 µg/mL) 
times as the control when minocycline was administered (Fig. 2).
1-Control
2-Minocycline only (4.59 μg/mL)
3-Cisplatin only (4 μg/mL)
4-Cisplatin only (8 μg/mL)
5-mino (4.59 μg/mL)+cis (4 μg/mL)
6-mino (4.59 μg/mL)+cis (8 μg/mL)
AIF
P-c-jun
Bcl-2
Cleaved PARP
Cleaved cas-3
GAPDH
  1  2  3  4  5  6
Fig. 2. Cells pretreated with 10 µM minocycline and cultured in 4 µg/
mL or 8 µg/mL cisplatin were analyzed using the Western blotting 
technique with antibodies targeting Bcl-2, p-JUN, cleaved cas-
pase-3, cleaved polymerase (PARP), and AIF. Bcl-2 expression was 
elevated after the pretreatment with minocycline. Minocycline pre-
treatment decreased cisplatin-induced cleaved caspase 3 activity 
at the 4 µg/mL, but not the 8 µg/mL dose. The expression of p-JUN, 
cleaved PARP, and apoptosis-inducing factor (AIF) increased by 
cisplatin treatment, and suppressed by minocycline pretreatment.
Fig. 3. The distribution (A) and mean amount (B) of hearing threshold shift in each group. The shift was greater in group 2 (white circle) than it 
was in group 1 (black circle). The threshold shift in the 16 Hz tone burst significantly different between the two groups. The threshold shift was 
less than 10 dB in two animals pretreated with minocycline.
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In vivo experiments
Auditory brainstem response
No change in hearing was observed in the minocycline-treated 
animals (group 3). The threshold elevation in group 1 was gener-
ally lower than that of group 2. Two animals (33%) in group 1 
even did not show any threshold shift. A significant protective 
effect of minocycline pretreatment was found for the 16 kHz 
tone (Mann-Whitney test, P<0.05) (Fig. 3).
SEM evaluation
Morphological evaluation of the SEM sections revealed that the 
basal and middle turns were more severely damaged than the 
apical turn. The inner hair cells were relatively well preserved in 
all turns compared with the OHCs in both groups 1 and 2 (Fig. 
4). However, more OHCs survived in group 1 compared with 
group 2. No morphological change was observed in SEM section 
of animals treated with minocycline (group 3). 
DISCUSSION
It is well known that two mitochondrial apoptotic pathways ex-
ist, the caspase-dependent and caspase-independent pathways. 
Caspase 3, the Bcl family, and cytochrome c (Cyt c) play impor-
tant roles in the caspase-dependent pathway. PARP-1-mediated 
cell death is caspase-independent and is considered to be “regu-
lated necrosis” because it lacks many of the morphological fea-
tures of classic apoptosis. Zong et al. (9) recently reported that 
in regulated necrosis, the cell actively initiates its death program 
following PARP-1 hyperactivation. Furthermore, it has been re-
ported that JNK, particularly JNK1, is required for PARP-induced 
mitochondrial dysfunction inducing AIF translocation and sub-
sequent cell death (10). AIF is an essential downstream element 
in PARP-1-mediated cell death. It moves into the nucleus and 
triggers nuclear DNA fragmentation which is an irreversible step 
in cell death. 
  Minocycline had been reported to prevent cell death by at 
least two mechanisms: attenuation of innate and adaptive im-
munity and blockade of apoptotic cascades (5). Minocycline at-
tenuates immunity through inhibition of microglial activation 
and proliferation, involving caspase-1, inducible nitric oxide 
synthetase, and cyclooxygenase 2. Additionally, minocycline in-
hibits adaptive immunity by reducing the expression of MMPs 
(11-14). Minocycline inhibits caspase-dependent and -indepen-
dent cell death induced by different stimuli in vitro, such as glu-
tamate, hydrogen peroxide, and tumor necrosis factor alpha 
(TNF-α) (15, 16). Up regulation of Bcl-2 produces a protective 
effect by antagonizing Bax and Bid, a family of death-promoting 
factors that elicit the release of Cyt c through the outer mito-
chondrial membrane (7).  Alano et al. (17) reported that PARP-
1 enzymatic activity can be directly inhibited by tetracycline de-
rivatives and minocycline was the most potent among them. 
JNK has been reported to have an important role in this apop-
totic pathway (10, 18).
  To determine the mechanism underlying minocycline protec-
tion against cisplatin-induced ototoxicity, we examined cleaved 
caspase-3, Bcl-2, cleaved PARP, AIF, and JNK, which are impor-
tant elements in the caspase-dependent and independent path-
ways. 
  Cleaved caspase 3 activity was also elevated following expo-
sure to cisplatin. Although addition of minocycline elevated Bcl-
2 activity after treatment with both concentrations of cisplatin, 
it could suppress cleaved caspase 3 activity stimulated only by 
lower, but not higher concentration of cisplatin. These findings 
indicate that minocycline does not effectively inhibit caspase-
dependent apoptosis stimulated by a high concentration of cis-
platin.
  HEI-OC1 cells expressed high levels of p-JUN, cleaved PARP, 
Fig. 4. Scanning electron micrographs of the basal turn of the organ 
of Corti. (A) In a hearing-preserved animal pretreated with minocy-
cline followed by cisplatin treatment, the outer hair cells are well pre-
served with minimal loss. (B) In an animal treated with cisplatin 
alone, catastrophic destruction occurred in the outer hair cells with 
fusion of cilia and bulla formation. The inner hair cells are relatively 
well preserved compared with the outer hair cells in both groups.
A B
Fig. 5. The cisplatin-induced apoptosis pathway in House Ear Insti-
tute-Organ of Corti 1 (HEI-OC1) cells and the proposed mechanism 
mediating the protective effect of minocycline. The black arrow () 
indicates activation, and the blocked arrow head () indicates inhi-
bition. Our data show that minocycline activates Bcl-2 and decreas-
es cleaved caspase-3, poly (ADP-ribose) polymerase (PARP), 
apoptosis-inducing factor (AIF) activity. These findings and those of 
previous studies suggest that minocycline activates Bcl-2 and inhib-
its downstream caspase-3 in the caspase-dependent pathway, and 
suppresses PARP-1 and downstream AIF in the caspase-indepen-
dent pathway.
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PARP-1
JNK1
RIP1 and TRAF2
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Cell Death
AIF
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and AIF, which are in the caspase-independent pathway follow-
ing exposure to 4 µg/mL and 8 µg/mL cisplatin. The increased 
expression of p-JUN and cleaved PARP decreased by 30-40% 
with pre-treatment with 10 µM minocycline. The expression of 
AIF also decreased by 20-40%. These findings suggest that mi-
nocycline inhibits PARP activity in the cell nucleus, followed by 
down regulation of JNK and AIF in the cytoplasm (18) (Fig. 5). 
Collectively, it can be suggested that cisplatin can induce ototox-
icity through two discrete pathways simultaneously, and that 
these pathways can partially be protected by minocycline.
  The in vivo experiments revealed that the shift in hearing 
threshold caused by cisplatin administration was partially atten-
uated by minocycline pretreatment. No change in hearing was 
observed in two animals of group 1. These results suggest the 
protective role of minocycline against cisplatin ototoxicity. 
Though a significant protection was observed only at 16 kHz, 
this partial effect can be attributed to the small number of ani-
mals tested.
  Evaluation of the SEM sections revealed that pretreatment 
with minocycline partially protected the OHCs at the basal and 
middle turn of the organ of Corti. The morphology of the OHCs 
was nearly normal in two animals that did not show a shift in 
the ABR threshold, and the animals with a significant hearing 
loss showed less severe morphological changes than those treat-
ed with cisplatin-alone. The diversity of the protective effect of 
minocycline may be explained by the difference of drug-host in-
teractions or susceptibility to cisplatin. Moreover, other studies 
suggest that cisplatin-induced ototoxicity in vivo may be medi-
ated by high-mobility group 1 (HMG1), inducible nitric oxide 
synthase (iNOS), Na
+, K
+-ATPase, and Ca
2+ ATPase and these 
various mechanisms of action, not protected by minocycline, 
may account for the differing responses to minocycline (19, 20). 
  In conclusion, minocycline may partially protect against cispl-
atin-induced ototoxicity in vitro and in vivo. Our findings sug-
gest that both caspase-dependent and independent pathways 
are involved in cisplatin-induced ototoxicity and also in the pro-
tective mechanism by minocycline.
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